# Cyclophosphamide and Rituximab Followed By Vaccine Therapy in Treating Patients With Chronic Lymphocytic Leukemia

> **NCT00343447** · PHASE2 · WITHDRAWN · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins**

## Conditions studied

- Leukemia

## Interventions

- **BIOLOGICAL:** autologous tumor cell vaccine
- **BIOLOGICAL:** rituximab
- **DRUG:** cyclophosphamide

## Key facts

- **NCT ID:** NCT00343447
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2006-08
- **Primary completion:** 2007-05
- **Final completion:** 2007-05
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2012-05-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00343447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00343447, "Cyclophosphamide and Rituximab Followed By Vaccine Therapy in Treating Patients With Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00343447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*